CareDx (NASDAQ:CDNA) Institutional Investor Sentiment Analysis

Sentiment for CareDx (NASDAQ:CDNA)

CareDx (NASDAQ:CDNA) institutional sentiment increased to 1.63 in 2019 Q2. Its up 0.05, from 1.58 in 2019Q1. The ratio is more positive, as 96 funds opened new and increased holdings, while 59 cut down and sold their equity positions in CareDx. The funds in our partner’s database now have: 38.15 million shares, up from 35.39 million shares in 2019Q1. Also, the number of funds holding CareDx in their top 10 holdings decreased from 5 to 4 for a decrease of 1. Sold All: 22 Reduced: 37 Increased: 64 New Position: 32.

CareDx, Inc., together with its subsidiaries, focuses on the discovery, development, and commercialization of diagnostic surveillance solutions for transplant patients in North America, Europe, the Middle East, Africa, and Latin America. The company has market cap of $1.19 billion. The firm operates through two divisions, CareDx and Olerup. It currently has negative earnings. The Company’s commercialized testing solution includes the AlloMap heart transplant molecular test , a gene expression test that helps clinicians monitor and identify heart transplant recipients with stable graft function who have a low probability of moderate/severe acute cellular rejection.

The stock increased 3.34% or $0.91 during the last trading session, reaching $28.15. About 768,378 shares traded. CareDx, Inc (NASDAQ:CDNA) has risen 170.83% since October 12, 2018 and is uptrending. It has outperformed by 170.83% the S&P500.

Analysts await CareDx, Inc (NASDAQ:CDNA) to report earnings on November, 14. They expect $-0.16 EPS, up 70.37 % or $0.38 from last year’s $-0.54 per share. After $-0.19 actual EPS reported by CareDx, Inc for the previous quarter, Wall Street now forecasts -15.79 % EPS growth.

Gagnon Securities Llc holds 7.87% of its portfolio in CareDx, Inc for 1.01 million shares. Gagnon Advisors Llc owns 293,785 shares or 6.04% of their US portfolio. Moreover, Next Century Growth Investors Llc has 3.28% invested in the company for 731,460 shares. The Minnesota-based Perkins Capital Management Inc has invested 3.19% in the stock. Rk Capital Management Llc, a Colorado-based fund reported 174,000 shares.

CareDx, Inc (NASDAQ:CDNA) Ratings Coverage

Ratings analysis reveals 100% of CareDx’s analysts are positive. Out of 2 Wall Street analysts rating CareDx, 2 give it “Buy”, 0 “Sell” rating, while 0 recommend “Hold”. The lowest target is $3000 while the high is $4800. The stock’s average target of $42 is 49.20% above today’s ($28.15) share price. CDNA was included in 4 notes of analysts from May 9, 2019. Raymond James maintained CareDx, Inc (NASDAQ:CDNA) rating on Friday, August 2. Raymond James has “Strong Buy” rating and $4800 target.

More notable recent CareDx, Inc (NASDAQ:CDNA) news were published by: Globenewswire.com which released: “CareDx Files Patent Infringement Lawsuit Against Natera – GlobeNewswire” on March 26, 2019, also Finance.Yahoo.com with their article: “Is CareDx, Inc’s (NASDAQ:CDNA) CEO Salary Justified? – Yahoo Finance” published on August 05, 2019, Investingnews.com published: “CareDx Files Lawsuit Against Eurofins Viracor | INN – Investing News Network” on September 26, 2019. More interesting news about CareDx, Inc (NASDAQ:CDNA) were released by: Fool.com and their article: “Here’s Why CareDx Stock Is Rising Today – Motley Fool” published on May 09, 2019 as well as Fool.com‘s news article titled: “CareDx, Inc (CDNA) Q1 2019 Earnings Call Transcript – The Motley Fool” with publication date: May 08, 2019.

CareDx, Inc (NASDAQ:CDNA) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.